van Ginkel Paul R, Darjatmoko Soesiawati R, Sareen Dhruv, Subramanian Lalita, Bhattacharya Saswati, Lindstrom Mary J, Albert Daniel M, Polans Arthur S
Department of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53792, USA.
Invest Ophthalmol Vis Sci. 2008 Apr;49(4):1299-306. doi: 10.1167/iovs.07-1233.
To test the efficacy of resveratrol, a nontoxic plant product, in the treatment of uveal melanoma.
The effect of oral administration and peritumor injection of resveratrol was tested on tumor growth in two animal models of uveal melanoma. The mechanism of resveratrol action on uveal melanoma cells was studied in vitro in a cell-viability assay: with JC-1 dye, to measure mitochondrial membrane potential; by Western blot analysis, to analyze the cellular redistribution of cytochrome c and Smac/diablo; and in a fluorescence assay with specific substrates, to measure activation of different caspases.
Resveratrol treatment inhibited tumor growth in animal models of uveal melanoma. Since oral administration resulted in relatively low bioavailability of resveratrol, the effect of increased local levels was tested by peritumor injection of the drug. This method resulted in tumor cell death and tumor regression. In vitro experiments with multiple uveal melanoma cell lines demonstrate that resveratrol causes a decrease in cell viability, resulting at least in part from an increase in apoptosis through a mitochondrial pathway. An early event in drug action is the direct targeting of mitochondria by resveratrol, which leads to a decrease in mitochondrial membrane potential and the eventual activation of caspase-3.
These data suggest that resveratrol can inhibit tumor growth and can induce apoptosis via the intrinsic mitochondrial pathway and that by further increasing bioavailability of resveratrol the potency of the drug can be increased, leading to tumor regression. The nontoxic nature of the drug at levels needed for therapy make resveratrol an attractive candidate for the treatment of uveal melanoma.
测试白藜芦醇(一种无毒植物产物)治疗葡萄膜黑色素瘤的疗效。
在两种葡萄膜黑色素瘤动物模型中,测试口服及瘤周注射白藜芦醇对肿瘤生长的影响。在体外细胞活力测定中研究白藜芦醇对葡萄膜黑色素瘤细胞的作用机制:用JC-1染料测量线粒体膜电位;通过蛋白质免疫印迹分析,分析细胞色素c和Smac/ Diablo的细胞内重新分布;并用特异性底物进行荧光测定,测量不同半胱天冬酶的激活情况。
白藜芦醇治疗可抑制葡萄膜黑色素瘤动物模型中的肿瘤生长。由于口服导致白藜芦醇的生物利用度相对较低,因此通过瘤周注射该药物来测试提高局部水平的效果。这种方法导致肿瘤细胞死亡和肿瘤消退。对多种葡萄膜黑色素瘤细胞系进行的体外实验表明,白藜芦醇可导致细胞活力下降,至少部分是由于通过线粒体途径增加凋亡所致。药物作用的早期事件是白藜芦醇直接靶向线粒体,这导致线粒体膜电位降低并最终激活半胱天冬酶-3。
这些数据表明,白藜芦醇可抑制肿瘤生长,并可通过内在线粒体途径诱导凋亡,并且通过进一步提高白藜芦醇的生物利用度可增强药物效力,导致肿瘤消退。该药物在治疗所需水平的无毒性质使白藜芦醇成为治疗葡萄膜黑色素瘤的有吸引力的候选药物。